首页 > 最新文献

Annales pharmaceutiques francaises最新文献

英文 中文
Feedback on a socio-aesthetic program for the benefit of young patients with self-endangerment. 对社会美学计划的反馈意见,以造福于有自我危险的年轻患者。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-07-09 DOI: 10.1016/j.pharma.2024.07.002
Céline Couteau, Marie Orieux, Christian Lainé, Rachel Bocher, Laurence Coiffard

Objectives: Socio-aesthetics is a practice born in psychiatric departments but has since developed particularly in the field of oncology. For our part, since January 2018, we have initiated an experiment of this type at the Espace Unit of the CHU in Nantes, a unit that takes care of young patients who find themselves in a situation of crisis and endangerment of themselves.

Methods: The qualitative evaluation of the interest of a socio-aesthetic mediation (relaxation modelling, facial care, make-up) with young patients was carried out by a collection of their feelings.

Results: Youth who expressed an overall judgment of socio-esthetic mediation appreciated it in 61% of cases. They express their satisfaction with words such as "I liked", "I loved", "I'm happy", "it was too good", "super good" or "great".

Conclusion: This successful socio-aesthetic therapy practice experiment will continue with a quantitative analysis to demonstrate the relevance of this type of service to psychiatric patients.

目的:- 社会美学是一种诞生于精神科的实践方法,但后来尤其在肿瘤学领域得到了发展。就我们而言,自 2018 年 1 月起,我们在南特市 CHU 的 Espace 病房开展了一项此类实验,该病房负责照顾处于危机和自身危险境地的年轻患者。方法:- 通过收集年轻患者的感受,对他们对社会美学调解(放松造型、面部护理、化妆)的兴趣进行定性评估:- 结果:对社会审美调解作出总体评价的年轻人中,61%的人对社会审美调解表示赞赏。他们用 "我喜欢"、"我爱"、"我很高兴"、"太好了"、"超级好 "或 "棒极了 "等词语表达自己的满意度。
{"title":"Feedback on a socio-aesthetic program for the benefit of young patients with self-endangerment.","authors":"Céline Couteau, Marie Orieux, Christian Lainé, Rachel Bocher, Laurence Coiffard","doi":"10.1016/j.pharma.2024.07.002","DOIUrl":"10.1016/j.pharma.2024.07.002","url":null,"abstract":"<p><strong>Objectives: </strong>Socio-aesthetics is a practice born in psychiatric departments but has since developed particularly in the field of oncology. For our part, since January 2018, we have initiated an experiment of this type at the Espace Unit of the CHU in Nantes, a unit that takes care of young patients who find themselves in a situation of crisis and endangerment of themselves.</p><p><strong>Methods: </strong>The qualitative evaluation of the interest of a socio-aesthetic mediation (relaxation modelling, facial care, make-up) with young patients was carried out by a collection of their feelings.</p><p><strong>Results: </strong>Youth who expressed an overall judgment of socio-esthetic mediation appreciated it in 61% of cases. They express their satisfaction with words such as \"I liked\", \"I loved\", \"I'm happy\", \"it was too good\", \"super good\" or \"great\".</p><p><strong>Conclusion: </strong>This successful socio-aesthetic therapy practice experiment will continue with a quantitative analysis to demonstrate the relevance of this type of service to psychiatric patients.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Stability-indicating HPLC for remogliflozin, vildagliptin, and metformin: Method development, validation, and greenness. 雷莫格列嗪、维达列汀和二甲双胍的稳定性指示高效液相色谱:方法开发、验证与绿色环保
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-06-28 DOI: 10.1016/j.pharma.2024.06.006
Himani Acharya, Rajendra Kotadiya

Objective: The present work represents a reverse-phase high-performance liquid chromatography method in addition to stability studies for sequential estimation of remogliflozin etabonate, vildagliptin, and metformin HCl in tablet formulation.

Method: The mentioned method utilizes a Phenomenex Luna C18 column (250×4.6mm, 5μm). It consists of a column oven's temperature of 35°C. Mobile phase includes a mixture of 50% phosphate buffer (pH - 6.8) and 50% acetonitrile along with a flow rate of 0.8mL/min and 20minutes of run time. The injection volume was 20μL; 217nm is a detection wavelength, and a PDA detector is used for detection.

Results: The suggested technique was proven and validated per the ICH Q2 (R1) guideline. The combination was put under stress conditions that included acid, base, thermal, photolytic, and oxidative degradation. The combination was considerably degraded under oxidative, acidic, and basic circumstances for deterioration, and the degradation results were accurately identified from the observed peaks, demonstrating the method's effectiveness in detecting stability.

Conclusion: The technique was quick, precise, sensitive, and accurate; as a result, it may be used in quality control laboratories and the pharmaceutical industry for routine quality monitoring of tablets containing all three medications.

目的本研究采用反相高效液相色谱法对片剂中依他羧酸雷莫格列汀、维达列汀和盐酸二甲双胍的含量进行了测定和稳定性研究:上述方法采用 Phenomenex Luna C18 色谱柱(250 × 4.6 mm,5 μm)。流动相为 50%磷酸盐缓冲液(pH - 6.8)和 50%乙腈的混合物,流速为 0.8 mL/min,运行时间为 20 分钟。进样量为 20 μL。检测波长为 217 nm,使用 PDA 检测器进行检测:结果:根据 ICH Q2(R1)指南,所建议的技术得到了证实和验证。将组合物置于压力条件下,包括酸、碱、热、光解和氧化降解。在氧化、酸性和碱性条件下,组合药剂发生了明显的降解变质,降解结果可从观察到的峰值中准确识别,证明了该方法在检测稳定性方面的有效性:结论:该技术快速、精确、灵敏、准确,因此可用于质量控制实验室和制药行业对含有这三种药物的片剂进行常规质量监测。
{"title":"Stability-indicating HPLC for remogliflozin, vildagliptin, and metformin: Method development, validation, and greenness.","authors":"Himani Acharya, Rajendra Kotadiya","doi":"10.1016/j.pharma.2024.06.006","DOIUrl":"10.1016/j.pharma.2024.06.006","url":null,"abstract":"<p><strong>Objective: </strong>The present work represents a reverse-phase high-performance liquid chromatography method in addition to stability studies for sequential estimation of remogliflozin etabonate, vildagliptin, and metformin HCl in tablet formulation.</p><p><strong>Method: </strong>The mentioned method utilizes a Phenomenex Luna C18 column (250×4.6mm, 5μm). It consists of a column oven's temperature of 35°C. Mobile phase includes a mixture of 50% phosphate buffer (pH - 6.8) and 50% acetonitrile along with a flow rate of 0.8mL/min and 20minutes of run time. The injection volume was 20μL; 217nm is a detection wavelength, and a PDA detector is used for detection.</p><p><strong>Results: </strong>The suggested technique was proven and validated per the ICH Q2 (R1) guideline. The combination was put under stress conditions that included acid, base, thermal, photolytic, and oxidative degradation. The combination was considerably degraded under oxidative, acidic, and basic circumstances for deterioration, and the degradation results were accurately identified from the observed peaks, demonstrating the method's effectiveness in detecting stability.</p><p><strong>Conclusion: </strong>The technique was quick, precise, sensitive, and accurate; as a result, it may be used in quality control laboratories and the pharmaceutical industry for routine quality monitoring of tablets containing all three medications.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141465828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanosuspensions: Enhancing drug bioavailability through nanonization. 纳米悬浮剂:通过纳米化提高药物的生物利用度。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-06-28 DOI: 10.1016/j.pharma.2024.06.003
Rohit Chavhan

Introduction: Nanosuspensions have emerged as a promising avenue in pharmaceutical innovation, particularly for enhancing the bioavailability of poorly soluble medications. This article explores the transformative potential of nanosuspensions, emphasizing the critical role of particle size reduction through nanonization techniques. With conventional approaches often falling short in addressing the bioavailability challenges of hydrophobic drugs, nanosuspensions offer multifaceted applications and distinctive advantages in drug delivery.

Methods: The study delves into various nanosuspension preparation techniques, including high-pressure homogenization, media milling, emulsification-solvent evaporation, precipitation, and supercritical fluid processes. Each method brings unique advantages and limitations, contributing to the expanding repertoire of nanosuspension formulation methods. The article emphasizes the necessity for meticulous planning, evaluation, and ongoing research across different drugs to optimize their use effectively.

Results: Nanosuspensions exhibit versatility in administration routes, spanning parenteral, peroral, ocular, and pulmonary pathways, making them applicable across diverse dosage forms. Current efforts are directed towards furthering their application in site-specific medication administration, indicating their potential in tailored therapeutic strategies. Nanosuspensions offer a promising solution for enhancing drug solubility and bioavailability, addressing the persistent challenge of poor solubility in pharmaceutical compounds.

Discussion: The significance of careful formulation and stabilization using polymers and surfactants is underscored, ensuring the efficacy and safety of nanosuspensions. By discussing the benefits, drawbacks, and nuances of each preparation technique, the article aims to simplify future research endeavors in the field of nanosuspensions. Additionally, a comprehensive overview of nanosuspensions, including their preparation methods, benefits, characterization, patents, marketed products, and intended uses, sheds light on this evolving domain in pharmaceutical sciences.

Conclusion: Nanosuspensions represent a promising approach for overcoming bioavailability challenges associated with poorly soluble medications. The article highlights their transformative potential in pharmaceutical innovation, emphasizing the importance of continued research and optimization to harness their benefits effectively. Nanosuspensions offer a viable solution for enhancing drug solubility and bioavailability, with implications for improving therapeutic outcomes in various medical conditions.

简介:纳米悬浮剂已成为医药创新中一条前景广阔的途径,尤其是在提高溶解性差的药物的生物利用度方面。本文探讨了纳米悬浮剂的变革潜力,强调了通过纳米化技术缩小粒径的关键作用。由于传统方法往往无法解决疏水性药物的生物利用度难题,纳米悬浮剂提供了多方面的应用和独特的给药优势:本研究深入探讨了各种纳米悬浮液制备技术,包括高压均质、介质研磨、乳化-溶剂蒸发、沉淀和超临界流体工艺。每种方法都有其独特的优势和局限性,从而使纳米悬浮液制备方法的种类不断增多。文章强调了对不同药物进行精心规划、评估和持续研究的必要性,以有效优化其使用:结果:纳米悬浮剂在给药途径上表现出多样性,包括肠外、口腔、眼部和肺部给药途径,使其适用于各种剂型。目前,纳米悬浮剂正致力于进一步应用于特定部位给药,这表明纳米悬浮剂在定制治疗策略方面具有潜力。纳米悬浮剂为提高药物溶解度和生物利用度提供了一种前景广阔的解决方案,解决了药物化合物溶解度低这一长期难题:讨论:强调了使用聚合物和表面活性剂进行精心配制和稳定的重要性,以确保纳米悬浮剂的有效性和安全性。通过讨论每种制备技术的优点、缺点和细微差别,文章旨在简化纳米悬浮剂领域未来的研究工作。此外,文章还全面概述了纳米悬浮剂,包括其制备方法、优点、表征、专利、上市产品和预期用途,从而揭示了制药科学中这一不断发展的领域:结论:纳米悬浮剂是克服与溶解性差的药物相关的生物利用度难题的一种前景广阔的方法。文章强调了纳米悬浮剂在医药创新中的变革潜力,并强调了持续研究和优化以有效利用其优势的重要性。纳米悬浮剂为提高药物溶解度和生物利用度提供了可行的解决方案,对改善各种病症的治疗效果具有重要意义。
{"title":"Nanosuspensions: Enhancing drug bioavailability through nanonization.","authors":"Rohit Chavhan","doi":"10.1016/j.pharma.2024.06.003","DOIUrl":"10.1016/j.pharma.2024.06.003","url":null,"abstract":"<p><strong>Introduction: </strong>Nanosuspensions have emerged as a promising avenue in pharmaceutical innovation, particularly for enhancing the bioavailability of poorly soluble medications. This article explores the transformative potential of nanosuspensions, emphasizing the critical role of particle size reduction through nanonization techniques. With conventional approaches often falling short in addressing the bioavailability challenges of hydrophobic drugs, nanosuspensions offer multifaceted applications and distinctive advantages in drug delivery.</p><p><strong>Methods: </strong>The study delves into various nanosuspension preparation techniques, including high-pressure homogenization, media milling, emulsification-solvent evaporation, precipitation, and supercritical fluid processes. Each method brings unique advantages and limitations, contributing to the expanding repertoire of nanosuspension formulation methods. The article emphasizes the necessity for meticulous planning, evaluation, and ongoing research across different drugs to optimize their use effectively.</p><p><strong>Results: </strong>Nanosuspensions exhibit versatility in administration routes, spanning parenteral, peroral, ocular, and pulmonary pathways, making them applicable across diverse dosage forms. Current efforts are directed towards furthering their application in site-specific medication administration, indicating their potential in tailored therapeutic strategies. Nanosuspensions offer a promising solution for enhancing drug solubility and bioavailability, addressing the persistent challenge of poor solubility in pharmaceutical compounds.</p><p><strong>Discussion: </strong>The significance of careful formulation and stabilization using polymers and surfactants is underscored, ensuring the efficacy and safety of nanosuspensions. By discussing the benefits, drawbacks, and nuances of each preparation technique, the article aims to simplify future research endeavors in the field of nanosuspensions. Additionally, a comprehensive overview of nanosuspensions, including their preparation methods, benefits, characterization, patents, marketed products, and intended uses, sheds light on this evolving domain in pharmaceutical sciences.</p><p><strong>Conclusion: </strong>Nanosuspensions represent a promising approach for overcoming bioavailability challenges associated with poorly soluble medications. The article highlights their transformative potential in pharmaceutical innovation, emphasizing the importance of continued research and optimization to harness their benefits effectively. Nanosuspensions offer a viable solution for enhancing drug solubility and bioavailability, with implications for improving therapeutic outcomes in various medical conditions.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141465868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Consensus update of the POPI tool]. [popi 工具的共识更新]。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-06-27 DOI: 10.1016/j.pharma.2024.06.004
Wala Ammor, Christele Gras Le Guen, François Angoulvant, Sonia Prot-Labarthe

Medication errors are one of the causes of iatrogenic medication use in children. The POPI tool for detecting inappropriate drug prescriptions and prescription omissions in paediatrics was the first tool to be published in this field in 2014. Our aim was to update the POPI tool for French use based on current recommendations and practice. Criteria were removed, updated or added based on recommendations from learned societies and national bodies. The two-round Delphi method was used to reach a consensus of experts. The level of agreement of the healthcare professionals' proposals was rated on a 9-point Likert scale. In the first round, only proposals with a median agreement of 7 to 9 and an agreement of more than 65% were retained. In the second round, only those with a median agreement of 7 to 9 and over 75% agreement were retained. The POPI tool now includes eight categories (various, infectiology, gastroenterology, pneumonology, dermatology, neurology/pedopsychiatry, haematology and excipients). All the criteria were supported by bibliographical references. They were submitted to 20 French healthcare professionals: 9 pharmacists and 11 doctors (17 hospital-based and 3 self-employed). After two rounds of Delphi testing, 166 criteria were retained and validated (111 inappropriate prescriptions and 55 omissions). In conclusion, this study made it possible to update the POPI tool, which is still available for assessing paediatric prescriptions.

用药错误是儿童先天性用药的原因之一。用于检测儿科不当用药处方和处方遗漏的 POPI 工具是该领域于 2014 年发布的首个工具。我们的目的是根据当前的建议和实践,更新 POPI 工具,供法国使用。根据学术团体和国家机构的建议,我们删除、更新或增加了一些标准。为了达成专家共识,我们采用了两轮德尔菲法。医护专业人员对建议的同意程度采用 9 分制的李克特量表进行评分。在第一轮中,只有同意度中位数为 7 至 9 且同意度超过 65% 的建议才会被采纳。在第二轮中,只有同意度中位数为 7 至 9 且同意度超过 75% 的建议书才被保留。POPI 工具目前包括八个类别(各种、感染学、肠胃病学、肺病学、皮肤病学、神经病学/儿 童精神病学、血液病学和辅料)。所有标准均有参考文献支持。这些标准提交给了 20 位法国医疗保健专业人士:其中包括 9 名药剂师和 11 名医生(17 名医院医生和 3 名个体医生)。经过两轮德尔菲测试,166 项标准得到保留和验证(111 项不当处方和 54 项遗漏)。总之,这项研究使 POPI 工具得以更新,该工具仍可用于评估儿科处方。
{"title":"[Consensus update of the POPI tool].","authors":"Wala Ammor, Christele Gras Le Guen, François Angoulvant, Sonia Prot-Labarthe","doi":"10.1016/j.pharma.2024.06.004","DOIUrl":"10.1016/j.pharma.2024.06.004","url":null,"abstract":"<p><p>Medication errors are one of the causes of iatrogenic medication use in children. The POPI tool for detecting inappropriate drug prescriptions and prescription omissions in paediatrics was the first tool to be published in this field in 2014. Our aim was to update the POPI tool for French use based on current recommendations and practice. Criteria were removed, updated or added based on recommendations from learned societies and national bodies. The two-round Delphi method was used to reach a consensus of experts. The level of agreement of the healthcare professionals' proposals was rated on a 9-point Likert scale. In the first round, only proposals with a median agreement of 7 to 9 and an agreement of more than 65% were retained. In the second round, only those with a median agreement of 7 to 9 and over 75% agreement were retained. The POPI tool now includes eight categories (various, infectiology, gastroenterology, pneumonology, dermatology, neurology/pedopsychiatry, haematology and excipients). All the criteria were supported by bibliographical references. They were submitted to 20 French healthcare professionals: 9 pharmacists and 11 doctors (17 hospital-based and 3 self-employed). After two rounds of Delphi testing, 166 criteria were retained and validated (111 inappropriate prescriptions and 55 omissions). In conclusion, this study made it possible to update the POPI tool, which is still available for assessing paediatric prescriptions.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141465866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of food on oral pharmacokinetics of edaravone coamorphous dispersion containing bile salts as coformers - Part II. 食物对以胆汁盐为辅剂的依达拉奉无定形分散剂口服药代动力学的影响--第二部分。
IF 1 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2024-06-26 DOI: 10.1016/j.pharma.2024.06.005
Dhrumi Patel, Sarika Wairkar

Objectives: Edaravone (EDR) is an effective neuroprotective agent in various neurological diseases; however, its use is restricted due to poor oral absorption. Bile salts are known for improving solubility and inhibiting drug crystallization in supersaturated conditions of the gastrointestinal tract (GIT). In our previous work, we prepared coamorphous dispersion (COAM) of EDR with sodium taurocholate (NaTC) using spray drying. The optimized EDR COAM exhibited superior in vitro performance compared to plain EDR. EDR is well absorbed in fasted-over-fed conditions.

Methods: The present work, we conducted a pharmacokinetic study for EDR and EDR COAM in fasted and fed conditions to check effect of food on its oral absorption. The LC-MS/MS-based method was developed and validated to determine the amount of EDR in plasma.

Results: The results suggested that EDR COAM did not show a significant difference in Cmax (P=0.3544) and AUC (P=0.1696) of fasted and fed states. On the other hand, plain EDR showed 2-fold and 3-fold reduced Cmax (P<0.0001) and AUC (P=0.0094) in the fed condition, respectively. The Cmax and AUC of EDR COAM were improved in fasted (AUC: 2.56-fold) and fed states (AUC: 5.74-fold) than plain EDR, suggesting better oral absorption of COAM than crystalline EDR without having the effect of food.

Conclusions: The unique structural attributes of NaTC had the potential to inhibit the recrystallization of EDR in GIT, while concurrently reducing the impact of food on the oral absorption of EDR.

目的:依达拉奉(Edaravone,EDR)是一种有效的神经保护剂,可用于治疗多种神经系统疾病,但由于口服吸收不良,其使用受到限制。众所周知,胆汁盐能提高药物的溶解度,抑制药物在胃肠道(GIT)过饱和条件下的结晶。在之前的研究中,我们采用喷雾干燥法制备了 EDR 与牛磺胆酸钠(NaTC)的共晶分散体(COAM)。与普通 EDR 相比,优化后的 EDR COAM 在体外表现出更优越的性能。EDR 在空腹-过食条件下吸收良好:本研究对 EDR 和 EDR COAM 在空腹和进食条件下的药代动力学进行了研究,以检测食物对其口服吸收的影响。结果表明,EDR 和 EDR COAM 在空腹和进食条件下的药代动力学研究中均呈阳性:结果表明,EDR COAM 在空腹和进食状态下的 Cmax(p=0.3544)和 AUC(p=0.1696)无显著差异。另一方面,普通 EDR 的 Cmax(pmax)和 AUC(AUC:5.74 倍)比 EDR 减少了 2 倍和 3 倍,表明 COAM 的口服吸收比结晶 EDR 好,且不受食物的影响:结论:NaTC 的独特结构属性有可能抑制 EDR 在胃肠道的再结晶,同时减少食物对 EDR 口服吸收的影响。
{"title":"Effect of food on oral pharmacokinetics of edaravone coamorphous dispersion containing bile salts as coformers - Part II.","authors":"Dhrumi Patel, Sarika Wairkar","doi":"10.1016/j.pharma.2024.06.005","DOIUrl":"10.1016/j.pharma.2024.06.005","url":null,"abstract":"<p><strong>Objectives: </strong>Edaravone (EDR) is an effective neuroprotective agent in various neurological diseases; however, its use is restricted due to poor oral absorption. Bile salts are known for improving solubility and inhibiting drug crystallization in supersaturated conditions of the gastrointestinal tract (GIT). In our previous work, we prepared coamorphous dispersion (COAM) of EDR with sodium taurocholate (NaTC) using spray drying. The optimized EDR COAM exhibited superior in vitro performance compared to plain EDR. EDR is well absorbed in fasted-over-fed conditions.</p><p><strong>Methods: </strong>The present work, we conducted a pharmacokinetic study for EDR and EDR COAM in fasted and fed conditions to check effect of food on its oral absorption. The LC-MS/MS-based method was developed and validated to determine the amount of EDR in plasma.</p><p><strong>Results: </strong>The results suggested that EDR COAM did not show a significant difference in C<sub>max</sub> (P=0.3544) and AUC (P=0.1696) of fasted and fed states. On the other hand, plain EDR showed 2-fold and 3-fold reduced C<sub>max</sub> (P<0.0001) and AUC (P=0.0094) in the fed condition, respectively. The C<sub>max</sub> and AUC of EDR COAM were improved in fasted (AUC: 2.56-fold) and fed states (AUC: 5.74-fold) than plain EDR, suggesting better oral absorption of COAM than crystalline EDR without having the effect of food.</p><p><strong>Conclusions: </strong>The unique structural attributes of NaTC had the potential to inhibit the recrystallization of EDR in GIT, while concurrently reducing the impact of food on the oral absorption of EDR.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141465867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The brown algae: Sargassum binderi sonder bears potential nephroprotective activity in in-vivo experimental model. 在体内实验模型中,褐藻马尾藻(Sargassum binderi sonder)显示出潜在的肾脏保护活性。
IF 1 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-06-11 DOI: 10.1016/j.pharma.2024.06.001
Nida Sohail, Hafiza Farhat, Shamim Akhtar Qureshi, Irfan Ullah, Muhammad Shaiq Ali

Objectives: This study aimed to investigate the protective activity of brown seaweed, the ethanolic and water extracts of Sargassum binderi (S. binderi) were examined. Anticancer drug, cisplatin is normally used for the treatment of solid tumors that cause acute kidney damage after assemblage in the renal tubules.

Material and methods: It was an acute nephrotoxicity study, animals were divided into several groups randomly, cisplatin (7mg/kg i.p.) and normal saline were used as positive and negative control respectively. The S. bindari ethanolic and water extract were given orally in a dose of 200mg/kg for 5days. Various biomarkers were assessed to observe the nephroprotective potential, while antioxidant activities were investigated using reduced glutathione, catalase and malondialdehyde as oxidative stress. GCMS was performed to validate the presence of important therapeutic moieties.

Results: The current result justified that pretreatment with S. binderi inhibited the elevation of antioxidant parameters and also showed protection against lipid peroxidation, induced by cisplatin challenge. The overall impact was the nephroprotection, which has been revealed from the results. GCMS evaluation of hexanes fraction revealed the presence of therapeutically important compounds including heptasiloxane, 3,7,11,15-tetramethyl-2-hexadecen-1-ol, hexadecamethyl, cyclooctasiloxane, and hexadecamethyl. These compounds have been reported for their antioxidant, antibacterial, anticancer, and antifungal activities.

Conclusion: S. binderi showed reno-protective effect by checking their well-known biochemical parameters probably due to the antioxidant activity as confirmed by the presence of compounds.

研究目的本研究旨在探讨乙醇(EtOH)和水(H2O)提取物对顺铂(抗癌药物)引发的肾毒性的保护作用。这种药物通常用于治疗实体瘤,在肾小管中聚集后会造成急性肾损伤:这是一项急性研究,动物被随机分为不同组,顺铂(7 毫克/千克,静脉注射)和生理盐水分别作为阳性和阴性对照。各组分别口服 S. bindari 的 EtOH 和 H2O 提取物,剂量为 200 毫克/千克,连服 5 天。根据肝肾生物标志物、电解质、血糖、血脂以及还原型谷胱甘肽、过氧化氢酶和丙二醛,研究了提取物的肾脏保护和抗氧化潜力。对 S.binderi 的己烷提取物进行了 GC-MS 分析,以评估其中是否含有重要的治疗化合物:结果:EtOH 和 H2O 提取物能有效降低肝肾生物标志物、血糖和血脂,使受顺铂影响的电解质恢复正常,并通过降低氧化应激提高抗氧化参数。对正己烷提取物的气相色谱-质谱(GC-MS)评价显示,S.binderi 中含有 21 种新化合物。其中,8-十七烯、十四酸甲酯、3,7,11,15-四甲基-2-十六烯-1-醇、十六酸甲酯被报告为抗氧化、抗炎、抗利尿和降胆固醇化合物:结论:S. binderi 具有保护肾脏的作用,它能稳定肾脏的相关生化指标,这可能是由于它具有抗氧化活性,这些化合物的存在证实了这一点。
{"title":"The brown algae: Sargassum binderi sonder bears potential nephroprotective activity in in-vivo experimental model.","authors":"Nida Sohail, Hafiza Farhat, Shamim Akhtar Qureshi, Irfan Ullah, Muhammad Shaiq Ali","doi":"10.1016/j.pharma.2024.06.001","DOIUrl":"10.1016/j.pharma.2024.06.001","url":null,"abstract":"<p><strong>Objectives: </strong>This study aimed to investigate the protective activity of brown seaweed, the ethanolic and water extracts of Sargassum binderi (S. binderi) were examined. Anticancer drug, cisplatin is normally used for the treatment of solid tumors that cause acute kidney damage after assemblage in the renal tubules.</p><p><strong>Material and methods: </strong>It was an acute nephrotoxicity study, animals were divided into several groups randomly, cisplatin (7mg/kg i.p.) and normal saline were used as positive and negative control respectively. The S. bindari ethanolic and water extract were given orally in a dose of 200mg/kg for 5days. Various biomarkers were assessed to observe the nephroprotective potential, while antioxidant activities were investigated using reduced glutathione, catalase and malondialdehyde as oxidative stress. GCMS was performed to validate the presence of important therapeutic moieties.</p><p><strong>Results: </strong>The current result justified that pretreatment with S. binderi inhibited the elevation of antioxidant parameters and also showed protection against lipid peroxidation, induced by cisplatin challenge. The overall impact was the nephroprotection, which has been revealed from the results. GCMS evaluation of hexanes fraction revealed the presence of therapeutically important compounds including heptasiloxane, 3,7,11,15-tetramethyl-2-hexadecen-1-ol, hexadecamethyl, cyclooctasiloxane, and hexadecamethyl. These compounds have been reported for their antioxidant, antibacterial, anticancer, and antifungal activities.</p><p><strong>Conclusion: </strong>S. binderi showed reno-protective effect by checking their well-known biochemical parameters probably due to the antioxidant activity as confirmed by the presence of compounds.</p>","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.0,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141316678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Review of the pharmacological properties of marine macroalgae used in the treatment of diabetes mellitus in Indonesia 印度尼西亚用于治疗糖尿病的海洋大型藻类药理特性综述。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-06-01 DOI: 10.1016/j.pharma.2024.02.006
Agung Giri Samudra , Agung Endro Nugroho , Retno Murwanti

Indonesia is the largest archipelagic country in the world, with 70% of its territory covered by oceans that are rich in various types of biological resources. Indonesia's biodiversity has made it possible to develop natural medicine. Marine algae have enormous potential, but the types of marine algae used still need to be more varied. Research on the pharmacology of marine macroalgae has been conducted in Indonesia, but studies on such topic related to diabetes mellitus (DM) still need to be completed. This study provides a comprehensive dataset of pharmacological anti-diabetic potential of marine macroalgae used for managing DM and reports on preclinical trials that provide pharmacological evidence. Data on the Indonesian marine macroalgae used to lower blood glucose were obtained from online sources. The bioactive chemicals of marine macroalgae have been found efficient at blocking several diabetes enzymes in in-vivo and in-vitro studies, and such chemicals have anti-inflammatory, anti-obesity, antioxidant, and other therapeutic benefits. The Google Scholar was used to search for the pharmacological literature with the keywords marine AND macroalgae AND diabetes AND Indonesia. Pharmacological research on the anti-diabetic activity of marine macroalgae has been carried out on five major Indonesian islands, including Sumatra, Kalimantan, Java, Sulawesi, and Papua, which encompassed 12 provinces: Southwest Papua, South Sulawesi, West Kalimantan, Riau Archipelago, Banten, West Java, North Sulawesi, East Java, Yogyakarta, Maluku, Jakarta, and Bengkulu. Articles on preclinical tests (in vitro and in vivo) were also used for the phytochemical problem section. The results briefly describe which class of algae has been widely used in Indonesia as an anti-diabetic. The findings of this research can be utilized to help find DM treatment drugs based on natural resources from marine macroalgae.

L’Indonésie est le plus grand pays archipélagique du monde, avec 70% de son territoire couvert par des océans riches en diverses ressources biologiques. La biodiversité indonésienne a permis de développer la médecine naturelle. Les algues marines ont un énorme potentiel, mais les types d’algues marines utilisées doivent encore être plus variés. Des recherches sur la pharmacologie des macroalgues marines ont été menées en Indonésie, mais des études sur des sujets liés au diabète sucré (DM) doivent encore être achevées. Cette étude fournit un ensemble de données complet sur le potentiel antidiabétique pharmacologique des macroalgues marines utilisées pour gérer la DM et des rapports sur des essais précliniques fournissant des preuves pharmacologiques. Les données sur les macroalgues marines indonésiennes utilisées pour abaisser la glycémie ont été obtenues à partir de sources en ligne. Les produits chimiques bioactifs des macroalgues marines se sont révélés efficaces pour bloquer plusieurs enzymes du diabète dans des études in vivo et in vitro

印度尼西亚是世界上最大的群岛国家,70%的领土被海洋覆盖,拥有丰富的各类生物资源。印尼的生物多样性为开发天然药物提供了可能。海洋藻类潜力巨大,但使用的海洋藻类种类仍需进一步丰富。印尼已经开展了有关海洋大型藻类药理学的研究,但与糖尿病(DM)相关的研究仍有待完成。本研究提供了用于控制糖尿病的海洋大型藻类的药理抗糖尿病潜力的综合数据集,并报告了提供药理证据的临床前试验。有关用于降低血糖的印尼海洋大型藻类的数据是从网上获取的。在体内和体外研究中发现,海洋大型藻类的生物活性化学物质能有效阻断几种糖尿病酶,这些化学物质具有抗炎、抗肥胖、抗氧化和其他治疗功效。我们使用谷歌学术搜索药理学文献,关键词为海洋、大型藻类、糖尿病、印度尼西亚。关于海洋大型藻类抗糖尿病活性的药理学研究已在印尼五大岛屿展开,包括苏门答腊岛、加里曼丹岛、爪哇岛、苏拉威西岛和巴布亚岛,涵盖 12 个省:巴布亚西南省、南苏拉威西省、西加里曼丹省、廖内群岛省、万丹省、西爪哇省、北苏拉威西省、东爪哇省、日惹省、马鲁古省、雅加达省和明古鲁省。植物化学问题部分还采用了临床前测试(体外和体内)的文章。研究结果简要介绍了印尼广泛使用的抗糖尿病藻类。本研究的结果可用于帮助寻找基于海洋大型藻类自然资源的糖尿病治疗药物。
{"title":"Review of the pharmacological properties of marine macroalgae used in the treatment of diabetes mellitus in Indonesia","authors":"Agung Giri Samudra ,&nbsp;Agung Endro Nugroho ,&nbsp;Retno Murwanti","doi":"10.1016/j.pharma.2024.02.006","DOIUrl":"10.1016/j.pharma.2024.02.006","url":null,"abstract":"<div><p>Indonesia is the largest archipelagic country in the world, with 70% of its territory covered by oceans that are rich in various types of biological resources. Indonesia's biodiversity has made it possible to develop natural medicine. Marine algae have enormous potential, but the types of marine algae used still need to be more varied. Research on the pharmacology of marine macroalgae has been conducted in Indonesia, but studies on such topic related to diabetes mellitus (DM) still need to be completed. This study provides a comprehensive dataset of pharmacological anti-diabetic potential of marine macroalgae used for managing DM and reports on preclinical trials that provide pharmacological evidence. Data on the Indonesian marine macroalgae used to lower blood glucose were obtained from online sources. The bioactive chemicals of marine macroalgae have been found efficient at blocking several diabetes enzymes in in-vivo and in-vitro studies, and such chemicals have anti-inflammatory, anti-obesity, antioxidant, and other therapeutic benefits. The Google Scholar was used to search for the pharmacological literature with the keywords marine AND macroalgae AND diabetes AND Indonesia. Pharmacological research on the anti-diabetic activity of marine macroalgae has been carried out on five major Indonesian islands, including Sumatra, Kalimantan, Java, Sulawesi, and Papua, which encompassed 12 provinces: Southwest Papua, South Sulawesi, West Kalimantan, Riau Archipelago, Banten, West Java, North Sulawesi, East Java, Yogyakarta, Maluku, Jakarta, and Bengkulu. Articles on preclinical tests (in vitro and in vivo) were also used for the phytochemical problem section. The results briefly describe which class of algae has been widely used in Indonesia as an anti-diabetic. The findings of this research can be utilized to help find DM treatment drugs based on natural resources from marine macroalgae.</p></div><div><p>L’Indonésie est le plus grand pays archipélagique du monde, avec 70% de son territoire couvert par des océans riches en diverses ressources biologiques. La biodiversité indonésienne a permis de développer la médecine naturelle. Les algues marines ont un énorme potentiel, mais les types d’algues marines utilisées doivent encore être plus variés. Des recherches sur la pharmacologie des macroalgues marines ont été menées en Indonésie, mais des études sur des sujets liés au diabète sucré (DM) doivent encore être achevées. Cette étude fournit un ensemble de données complet sur le potentiel antidiabétique pharmacologique des macroalgues marines utilisées pour gérer la DM et des rapports sur des essais précliniques fournissant des preuves pharmacologiques. Les données sur les macroalgues marines indonésiennes utilisées pour abaisser la glycémie ont été obtenues à partir de sources en ligne. Les produits chimiques bioactifs des macroalgues marines se sont révélés efficaces pour bloquer plusieurs enzymes du diabète dans des études in vivo et in vitro","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139734293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The cost of multiple myeloma and its complications: A single-center study from Oran, Algeria 多发性骨髓瘤及其并发症的代价:阿尔及利亚奥兰的一项单中心研究。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-06-01 DOI: 10.1016/j.pharma.2024.02.001
Fairouz Haouatti , Ikram K. Belhadj , Ahlem Goumidi , Nabil Yafour , Houari Toumi

Background

The expenses of multiple myeloma (MM) represent a real economic and societal burden for patients and health authorities. However, very little is known about the situation in Algeria. Therefore, the aim of this study is to evaluate the costs generated by the management of MM and its complications in Algerian patients.

Materials and methods

An observational retrospective study conducted on patients diagnosed with MM, from January 1st, 2019 to April 31st, 2023, at the Establishment Hospitalier Universitaire November 1st, Oran. A bottom-up costing methodology was used to assess the phase-specific cost and the complication burden.

Results

In total, 249 qualified for the study. For autologous stem cell transplantation (ASCT) eligible patients, the mean per patient cost of treating myeloma was estimated at: induction regimen ($4072); ASCT ($2899); consolidation ($1538); and maintenance ($355.76). The mean drug cost for ASCT-ineligible patients was $1421. The use of generic bortezomib and generic melphalan has led to a reduction in expenses of $1,075,181 ($5,024 per patient; 55.35%) and $10,864 ($487 per patient; 15.07%), respectively. Another cost-saving adaptation was ASCT using non-cryopreserved (NC) stem cells. The cost of managing MM complications was $177,782 per year.

Conclusion

A number of adjustments have been implemented to the management of MM over time to improve clinical efficacy and reduce costs in Algeria. However, this may have come with a startlingly high cost of complications.

Contexte

Les dépenses liées au myélome multiple (MM) représentent un véritable fardeau économique et sociétal pour les patients et les autorités sanitaires. Cependant, la situation en Algérie est très peu connue. L’objectif de cette étude est donc d’évaluer les coûts générés par la prise en charge du MM et de ses complications chez les patients algériens.

Matériels et méthodes

Une étude rétrospective observationnelle menée sur des patients diagnostiqués avec un MM, du 1er janvier 2019 au 31 avril 2023, à l’établissement hospitalier universitaire du 1er novembre, Oran. Une méthodologie de calcul des coûts ascendants a été utilisée pour évaluer le coût spécifique à la phase et des complications.

Résultats

Au total, 249 personnes se sont qualifiées pour l’étude. Pour les patients éligibles à une autogreffe de cellules souches (ASCT), le coût moyen par patient du traitement du myélome a été estimé à : régime d’induction (4072 $) ; ASCT (2899 $) ; consolidation (1538 $) ; et maintenance (356 $). Le coût moyen des médicaments pour les patients non éligibles à l’ASCT était de 1421 $. L’utilisation de bortezomib générique et de melphalan générique a entraîné une réduction des dépenses de 1 075 181 $ (5024 $ par patient ; 55,35 %) et de 10 864 $ (487,10 $ par patient ; 15,07 %)

背景:多发性骨髓瘤(MM)的费用对患者和卫生部门来说是一项实际的经济和社会负担。然而,人们对阿尔及利亚的情况知之甚少。因此,本研究旨在评估阿尔及利亚患者因治疗多发性骨髓瘤及其并发症而产生的费用。材料与方法:这是一项观察性回顾研究,对象是 2019 年 1 月 1 日至 2023 年 4 月 31 日期间确诊为多发性骨髓瘤的患者。研究地点:奥兰市十一月一日大学医院。研究采用了自下而上的成本计算方法,以评估特定阶段的成本和并发症负担。自体干细胞移植(ASCT)合格患者治疗骨髓瘤的人均成本估计为:诱导方案(407198美元);ASCT(289925美元);巩固治疗(153818美元);维持治疗(35576美元)。不符合 ASCT 条件的患者的平均药物成本为 1 421 52 美元。使用非专利硼替佐米和非专利美法仑使费用分别减少了 1 075 181 25 美元(每位患者 5 024 21 美元;55.35%)和 10 864 24 美元(每位患者 487 10 美元;15.07%)。另一种节约成本的适应方法是使用非干细胞保存(NC)干细胞进行ASCT。管理MM并发症的成本为每年17778198美元:随着时间的推移,阿尔及利亚对MM的管理进行了一系列调整,以提高临床疗效并降低成本。然而,这可能伴随着惊人的并发症成本。
{"title":"The cost of multiple myeloma and its complications: A single-center study from Oran, Algeria","authors":"Fairouz Haouatti ,&nbsp;Ikram K. Belhadj ,&nbsp;Ahlem Goumidi ,&nbsp;Nabil Yafour ,&nbsp;Houari Toumi","doi":"10.1016/j.pharma.2024.02.001","DOIUrl":"10.1016/j.pharma.2024.02.001","url":null,"abstract":"<div><h3>Background</h3><p>The expenses of multiple myeloma (MM) represent a real economic and societal burden for patients and health authorities. However, very little is known about the situation in Algeria. Therefore, the aim of this study is to evaluate the costs generated by the management of MM and its complications in Algerian patients.</p></div><div><h3>Materials and methods</h3><p>An observational retrospective study conducted on patients diagnosed with MM, from January 1st, 2019 to April 31st, 2023, at the Establishment Hospitalier Universitaire November 1st, Oran. A bottom-up costing methodology was used to assess the phase-specific cost and the complication burden.</p></div><div><h3>Results</h3><p>In total, 249 qualified for the study. For autologous stem cell transplantation (ASCT) eligible patients, the mean per patient cost of treating myeloma was estimated at: induction regimen ($4072); ASCT ($2899); consolidation ($1538); and maintenance ($355.76). The mean drug cost for ASCT-ineligible patients was $1421. The use of generic bortezomib and generic melphalan has led to a reduction in expenses of $1,075,181 ($5,024 per patient; 55.35%) and $10,864 ($487 per patient; 15.07%), respectively. Another cost-saving adaptation was ASCT using non-cryopreserved (NC) stem cells. The cost of managing MM complications was $177,782 per year.</p></div><div><h3>Conclusion</h3><p>A number of adjustments have been implemented to the management of MM over time to improve clinical efficacy and reduce costs in Algeria. However, this may have come with a startlingly high cost of complications.</p></div><div><h3>Contexte</h3><p>Les dépenses liées au myélome multiple (MM) représentent un véritable fardeau économique et sociétal pour les patients et les autorités sanitaires. Cependant, la situation en Algérie est très peu connue. L’objectif de cette étude est donc d’évaluer les coûts générés par la prise en charge du MM et de ses complications chez les patients algériens.</p></div><div><h3>Matériels et méthodes</h3><p>Une étude rétrospective observationnelle menée sur des patients diagnostiqués avec un MM, du 1<sup>er</sup> janvier 2019 au 31 avril 2023, à l’établissement hospitalier universitaire du 1<sup>er</sup> novembre, Oran. Une méthodologie de calcul des coûts ascendants a été utilisée pour évaluer le coût spécifique à la phase et des complications.</p></div><div><h3>Résultats</h3><p>Au total, 249 personnes se sont qualifiées pour l’étude. Pour les patients éligibles à une autogreffe de cellules souches (ASCT), le coût moyen par patient du traitement du myélome a été estimé à : régime d’induction (4072 $) ; ASCT (2899 $) ; consolidation (1538 $) ; et maintenance (356 $). Le coût moyen des médicaments pour les patients non éligibles à l’ASCT était de 1421 $. L’utilisation de bortezomib générique et de melphalan générique a entraîné une réduction des dépenses de 1 075 181 $ (5024 $ par patient ; 55,35 %) et de 10 864 $ (487,10 $ par patient ; 15,07 %)","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139715762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strategy to secure the neuraxial route in anaesthesia: Risk mapping and feedback from the application of the ISO 80369-6 standard NRFit® connectors 确保麻醉中神经通路安全的策略:应用 ISO 80369-6 标准 NRFit® 连接器的风险测绘和反馈。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-06-01 DOI: 10.1016/j.pharma.2024.02.015
Jeanice Amiot , Marie Hélène Bruge Ansel , Mathilde Bruyas , Marc Rinaudo , Emilie Rulliat , Jérôme Gauthier , Vincent Piriou , Delphine Cabelguenne

Introduction

In anesthesia, a medication error would occur every 20 to 133 anesthesia procedures, and 14% is related to a route administration error. To secure neuraxial route, ISO group published a norm in 2016 to develop specific connectors, the “NRFit® connector”. The main objective of this work, is to develop a risk mapping related to neuraxial medication errors therefore prepare the NRFit® implementation in anesthesia units in a French Universitary Hospital.

Methods

Failure modes, effects and criticality analysis (FMECA) methodology was used for our risk mapping which was divided in 3 anesthesia specialities. For each, the analysis was performed for accidental neuraxial administration of intravenous drugs, and its opposite error. Secondly, NRFit® devices were tested for 1 month by 3 experimented anesthetists.

Results

The majority of reported errors concerns epidural and intrathecal anesthesia, and more frequently in the field of obstetrics. Opioids and tranexamic acid, administered in neuraxial route, are drugs with the highest criticality. The tests were rather conclusive and made it possible to highlight the additional needs in medical devices.

Discussion

Obstetrics is the riskiest area due to the frequency of epidural anesthesia, the administration of critical drugs in intravenous and neuraxial route. This work increased the awareness of our group, improved the measure of this risk and harmonized practices.

Conclusion

This work is the first step of the project to prevent administration route error in anesthesia during patient's drug management. The next step will be the NRFit® implementation for epidural and combined spinal-epidural anesthesia in our hospital.

Introduction

En Anesthésie, une erreur médicamenteuse surviendrait toutes les 20 à 133 procédures, et 14 % sont liées à une erreur de voie d’administration. Pour sécuriser la voie neuraxiale, la norme ISO 80369-6 propose une connectique dédiée, la connectique « NRFit® ». Le principal objectif de ce travail est de réaliser une cartographie des risques concernant les erreurs médicamenteuses en lien avec cette voie, afin de préparer la transition à la connectique NRFit® en Anesthésie.

Méthodologie

La méthodologie Analyse des modes de défaillance, de leurs effets et de leur criticité (AMDEC) a été utilisée. Il a été analysé les administrations accidentelles neuraxiales de médicaments destinés à la voie intraveineuse, ainsi que l’erreur opposée. Puis, les dispositifs médicaux NRFit® ont été testés pendant 1 mois par 3 anesthésistes expérimentés.

Résultats

La majorité des erreurs publiées concernent l’anesthésie péridurale et intrathécale, et plus fréquemment dans le domaine de l’obstétrique. Les opioïdes et l’acide tranexamique, administrés par voie neuraxiale, sont les médicaments les plus critiques

导言:在麻醉领域,每 20 到 133 个麻醉程序中就会发生一次用药错误,其中 14% 与给药途径错误有关。为确保神经经路的安全,ISO 小组于 2016 年发布了一项规范,以开发特定的连接器,即 "NRFit® 连接器"。这项工作的主要目的是绘制与神经通路用药错误有关的风险图,从而为在法国一所大学医院的麻醉科实施 NRFit® 做好准备:方法:在绘制风险图时采用了 FMECA(失效模式、影响和临界度分析)方法,将风险图分为 3 个麻醉专科。每个专科都对意外的神经经脉静脉给药及其相反的错误进行了分析。其次,3 名麻醉师对 NRFit® 设备进行了为期 1 个月的测试:结果:报告的大多数错误涉及硬膜外和鞘内麻醉,在产科领域更为常见。通过神经经路给药的阿片类药物和氨甲环酸是关键性最高的药物。这些测试结果相当可靠,可以突出说明医疗设备的额外需求:讨论:产科是风险最大的领域,因为硬膜外麻醉、静脉注射和神经经路给药都很频繁。这项工作提高了我们小组的认识,改进了对这一风险的测量,并协调了各种做法:这项工作是项目的第一步,目的是在病人用药过程中预防麻醉给药途径错误。下一步,我们医院将在硬膜外麻醉和脊髓硬膜外联合麻醉中实施 NRFit®。
{"title":"Strategy to secure the neuraxial route in anaesthesia: Risk mapping and feedback from the application of the ISO 80369-6 standard NRFit® connectors","authors":"Jeanice Amiot ,&nbsp;Marie Hélène Bruge Ansel ,&nbsp;Mathilde Bruyas ,&nbsp;Marc Rinaudo ,&nbsp;Emilie Rulliat ,&nbsp;Jérôme Gauthier ,&nbsp;Vincent Piriou ,&nbsp;Delphine Cabelguenne","doi":"10.1016/j.pharma.2024.02.015","DOIUrl":"10.1016/j.pharma.2024.02.015","url":null,"abstract":"<div><h3>Introduction</h3><p>In anesthesia, a medication error would occur every 20 to 133 anesthesia procedures, and 14% is related to a route administration error. To secure neuraxial route, ISO group published a norm in 2016 to develop specific connectors, the “NRFit® connector”. The main objective of this work, is to develop a risk mapping related to neuraxial medication errors therefore prepare the NRFit® implementation in anesthesia units in a French Universitary Hospital.</p></div><div><h3>Methods</h3><p>Failure modes, effects and criticality analysis (FMECA) methodology was used for our risk mapping which was divided in 3 anesthesia specialities. For each, the analysis was performed for accidental neuraxial administration of intravenous drugs, and its opposite error. Secondly, NRFit® devices were tested for 1 month by 3 experimented anesthetists.</p></div><div><h3>Results</h3><p>The majority of reported errors concerns epidural and intrathecal anesthesia, and more frequently in the field of obstetrics. Opioids and tranexamic acid, administered in neuraxial route, are drugs with the highest criticality. The tests were rather conclusive and made it possible to highlight the additional needs in medical devices.</p></div><div><h3>Discussion</h3><p>Obstetrics is the riskiest area due to the frequency of epidural anesthesia, the administration of critical drugs in intravenous and neuraxial route. This work increased the awareness of our group, improved the measure of this risk and harmonized practices.</p></div><div><h3>Conclusion</h3><p>This work is the first step of the project to prevent administration route error in anesthesia during patient's drug management. The next step will be the NRFit® implementation for epidural and combined spinal-epidural anesthesia in our hospital.</p></div><div><h3>Introduction</h3><p>En Anesthésie, une erreur médicamenteuse surviendrait toutes les 20 à 133 procédures, et 14 % sont liées à une erreur de voie d’administration. Pour sécuriser la voie neuraxiale, la norme ISO 80369-6 propose une connectique dédiée, la connectique « NRFit® ». Le principal objectif de ce travail est de réaliser une cartographie des risques concernant les erreurs médicamenteuses en lien avec cette voie, afin de préparer la transition à la connectique NRFit® en Anesthésie.</p></div><div><h3>Méthodologie</h3><p>La méthodologie Analyse des modes de défaillance, de leurs effets et de leur criticité (AMDEC) a été utilisée. Il a été analysé les administrations accidentelles neuraxiales de médicaments destinés à la voie intraveineuse, ainsi que l’erreur opposée. Puis, les dispositifs médicaux NRFit® ont été testés pendant 1 mois par 3 anesthésistes expérimentés.</p></div><div><h3>Résultats</h3><p>La majorité des erreurs publiées concernent l’anesthésie péridurale et intrathécale, et plus fréquemment dans le domaine de l’obstétrique. Les opioïdes et l’acide tranexamique, administrés par voie neuraxiale, sont les médicaments les plus critiques","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140048664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antioxidant and cytotoxicity activity of a nanoemulsion from Satureja kermanica (Lamiaceae) Satureja kermanica(唇形科植物)纳米乳液的抗氧化性和细胞毒性活性。
IF 1.3 Q3 Pharmacology, Toxicology and Pharmaceutics Pub Date : 2024-06-01 DOI: 10.1016/j.pharma.2024.01.005
Navid Hassanabadi , Zahra Mahdavi Meymand , Anis Ashrafzadeh , Fariba Sharififar

Objective

Satureja kermanica is a native species with a relatively wide distribution in Iran, which has been studied less. Due to the low stability of the plants, in this study, the methanolic extract of S. kermanica (MSK) along with a nanoemulsion (NEK) preparation was evaluated in terms of antioxidant and cytotoxic activity.

Material and methods

The aerial parts of S. kermanica were collected and after studying the organoleptic characteristics and quality control parameters, were extracted with methanol. Total phenolic compounds and total flavonoids of the plant were measured. A nanoemulsion preparation was prepared using ultrasonication method from S. kermanica extract. After measuring the particle size of nanoemulsion, both MSK and NEK were evaluated for their antioxidant and cytotoxic activity using DPPH scavenging assay and MTT colorimetric method on breast cancer cell line (MCF-7) respectively.

Results

Phytochemical studies exhibited the presence of secondary metabolites including flavonoids, tannins, steroids and carbohydrates in the plant. Based on the histogram of the SBL nanosizer, the average diameter of nanoemulsion was determined as 37.09 nm. Both MSK and NEK showed dose-dependent antioxidant and cytotoxic activity. The IC50 value of MSK and NEK for DPPH inhibition was 30.105 ± 2.781 58.14 ± 0.84 μg/mL and for toxicity toward MCF-7 cell line was 1251.088 and 201.745 ± 4.554 μg/mL respectively.

Conclusion

MSK and NEK showed antioxidant and cytotoxic activity, but in NEK, the antioxidant and cytotoxic potential of the plant was more prominent, which may be due to the rapid release of the bioactive component from the nanoemulsion.

Objectif

Satureja kermanica est une espèce indigène avec une répartition relativement large en Iran, qui a été moins étudiée. En raison de la faible stabilité des plantes, dans cette étude, l’extrait méthanolique de S. kermanica (MSK) ainsi qu’une préparation de nanoémulsion (NEK) ont été évalués en termes d’activité antioxydante et cytotoxique.

Matériel et méthodes

Les parties aériennes de S. kermanica ont été collectées et après étude des caractéristiques organoleptiques et des paramètres de contrôle qualité, ont été extraites au méthanol. Les composés phénoliques totaux et les flavonoïdes totaux de la plante ont été mesurés. Une préparation de nanoémulsion a été préparée en utilisant la méthode de sonication à partir d’un extrait de S. kermanica. Après avoir mesuré la taille des particules de la nanoémulsion, MSK et NEK ont été évalués pour leur activité antioxydante et cytotoxique à l’aide du test de piégeage DPPH et de la méthode colorimétrique MTT sur la lignée cellulaire du cancer du sein (MCF-

目的:Satureja kermanica 是一种原生植物,在伊朗分布较广,但研究较少。由于植物的稳定性较低,本研究对 S. kermanica 的甲醇提取物(MSK)和纳米乳液(NEK)制剂的抗氧化性和细胞毒性活性进行了评估:材料和方法:采集 S. kermanica 的气生部分,研究其感官特征和质量控制参数后,用甲醇提取。测定了植物的总酚类化合物和总黄酮类化合物。用超声波法从 S. kermanica 提取物中制备纳米乳液。测量纳米乳液的粒度后,分别使用 DPPH 清除法和 MTT 比色法对 MSK 和 NEK 在乳腺癌细胞系(MCF- 7)上的抗氧化性和细胞毒性活性进行了评估:植物化学研究表明,该植物中含有黄酮类、单宁酸、类固醇和碳水化合物等次生代谢物。根据 SBL 纳米粒度仪的直方图,确定纳米乳液的平均直径为 37.09 nm。MSK 和 NEK 都表现出剂量依赖性的抗氧化和细胞毒性活性。MSK 和 NEK 抑制 DPPH 的 IC50 值分别为 30.105 ± 2.781 58.14 ± 0.84μg/ml ,对 MCF-7 细胞株的毒性分别为 1251.088 和 201.745 ± 4.554 µg/ml:MSK和NEK具有抗氧化和细胞毒性活性,但在NEK中,植物的抗氧化和细胞毒性潜力更为突出,这可能是由于生物活性成分从纳米乳液中快速释放所致。
{"title":"Antioxidant and cytotoxicity activity of a nanoemulsion from Satureja kermanica (Lamiaceae)","authors":"Navid Hassanabadi ,&nbsp;Zahra Mahdavi Meymand ,&nbsp;Anis Ashrafzadeh ,&nbsp;Fariba Sharififar","doi":"10.1016/j.pharma.2024.01.005","DOIUrl":"10.1016/j.pharma.2024.01.005","url":null,"abstract":"<div><h3>Objective</h3><p><em>Satureja kermanica</em> is a native species with a relatively wide distribution in Iran, which has been studied less. Due to the low stability of the plants, in this study, the methanolic extract of <em>S. kermanica</em> (MSK) along with a nanoemulsion (NEK) preparation was evaluated in terms of antioxidant and cytotoxic activity.</p></div><div><h3>Material and methods</h3><p>The aerial parts of <em>S. kermanica</em> were collected and after studying the organoleptic characteristics and quality control parameters, were extracted with methanol. Total phenolic compounds and total flavonoids of the plant were measured. A nanoemulsion preparation was prepared using ultrasonication method from <em>S. kermanica</em> extract. After measuring the particle size of nanoemulsion, both MSK and NEK were evaluated for their antioxidant and cytotoxic activity using DPPH scavenging assay and MTT colorimetric method on breast cancer cell line (MCF-7) respectively.</p></div><div><h3>Results</h3><p>Phytochemical studies exhibited the presence of secondary metabolites including flavonoids, tannins, steroids and carbohydrates in the plant. Based on the histogram of the SBL nanosizer, the average diameter of nanoemulsion was determined as 37.09<!--> <!-->nm. Both MSK and NEK showed dose-dependent antioxidant and cytotoxic activity. The IC<sub>50</sub> value of MSK and NEK for DPPH inhibition was 30.105<!--> <!-->±<!--> <!-->2.781 58.14<!--> <!-->±<!--> <!-->0.84<!--> <!-->μg/mL and for toxicity toward MCF-7 cell line was 1251.088 and 201.745<!--> <!-->±<!--> <!-->4.554<!--> <!-->μg/mL respectively.</p></div><div><h3>Conclusion</h3><p>MSK and NEK showed antioxidant and cytotoxic activity, but in NEK, the antioxidant and cytotoxic potential of the plant was more prominent, which may be due to the rapid release of the bioactive component from the nanoemulsion.</p></div><div><h3>Objectif</h3><p><em>Satureja kermanica</em> est une espèce indigène avec une répartition relativement large en Iran, qui a été moins étudiée. En raison de la faible stabilité des plantes, dans cette étude, l’extrait méthanolique de <em>S. kermanica</em> (MSK) ainsi qu’une préparation de nanoémulsion (NEK) ont été évalués en termes d’activité antioxydante et cytotoxique.</p></div><div><h3>Matériel et méthodes</h3><p>Les parties aériennes de <em>S. kermanica</em> ont été collectées et après étude des caractéristiques organoleptiques et des paramètres de contrôle qualité, ont été extraites au méthanol. Les composés phénoliques totaux et les flavonoïdes totaux de la plante ont été mesurés. Une préparation de nanoémulsion a été préparée en utilisant la méthode de sonication à partir d’un extrait de <em>S. kermanica</em>. Après avoir mesuré la taille des particules de la nanoémulsion, MSK et NEK ont été évalués pour leur activité antioxydante et cytotoxique à l’aide du test de piégeage DPPH et de la méthode colorimétrique MTT sur la lignée cellulaire du cancer du sein (MCF-","PeriodicalId":8332,"journal":{"name":"Annales pharmaceutiques francaises","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139569702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Annales pharmaceutiques francaises
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1